October 9, 2015
Recommended Topic Related To:


"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.

GCTB generally occurs in a"...




Clinical consequences of overdosage with OptiMARK have not been reported. Treatment of overdose is directed toward supporting vital functions and prompt institution of symptomatic therapy. OptiMARK has been shown to be dialyzable [see CLINICAL PHARMACOLOGY].


OptiMARK is contraindicated in patients with:

  • chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²)
  • acute kidney injury
  • known hypersensitivity reactions to gadolinium, versetamide or any of the inert ingredients.

Last reviewed on RxList: 12/15/2014
This monograph has been modified to include the generic and brand name in many instances.


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.